CD40 and systemic lupus erythematosus: Inhibitions of T/B cell co-stimulatory pathway such as CD40-CD40L lead to the effective improvement of disease progression in lupus mice, but unexpected thromboembolic events have been reported during the pre-clinic trials of anti-CD40L antibodies.